Study S000963

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01917656
Acronym: LIRA-Ramadan™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 343
Start: 2014-01-09
Primary completion: 2014-09-01
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:metformin; DRUG:sulphonylurea
Results posted: TRUE
Secondary identifiers: OTHER:U1111-1132-9716

Registered primary outcomes

Change in Fructosamine From Start of Ramadan to End of Ramadan [Day -1, day 29]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023732	Interventions for people with type 2 diabetes mellitus fasting during Ramadan. Lee SWH, The Cochrane database of systematic reviews	2023	Systematic review	PMID 37435938 DOI	cites ClinicalTrials.gov:NCT01917656; registry reference DERIVED:37435938
R0025756	Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial. Azar ST, Diabetes, obesity & metabolism	2016	Randomized trial	PMID 27376711 DOI	cites ClinicalTrials.gov:NCT01917656; registry reference RESULT:27376711